PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))))) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI). Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.
Adobe, Phillips 66 And 2 Major ETFs: CNBC’s ‘Final Trades’
On CNBC’s "Halftime Report Final Trades," Josh Brown of Ritholtz Wealth Management said he is sticking with iShares U.S.
